Submucosal injection of the RNA oligonucleotide GUT-1 in active ulcerative colitis patients: A randomized, double-blind, placebo-controlled phase 2a induction trial.
Gisela FeltenTanja KühbacherMaximilian J WaldnerSimon HirschmannOliver DrvarovRaed Abu HashemChristian MaaserTorsten KucharzikJohanna DinterJessica MertensChristoph SchrammBabett HollerJoachim MössnerKenji SuzukiJunji YokoyamaShuji TeraiWolfgang UterHiroyuki YoneyamaHitoshi AsakuraToshifumi HibiMarkus F NeurathPublished in: Journal of Crohn's & colitis (2023)
Single dosing by submucosal injection of GUT-1 repressed CHST15 mucosal expression and may represent a novel induction therapy by modulating tissue remodeling in UC.
Keyphrases
- placebo controlled
- double blind
- ulcerative colitis
- phase iii
- study protocol
- end stage renal disease
- phase ii
- clinical trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- poor prognosis
- peritoneal dialysis
- ultrasound guided
- stem cells
- signaling pathway
- radiation therapy
- long non coding rna
- cell therapy
- patient reported